All In Biotech

Drug Trial Radar · NCT07578649

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

AN INTERVENTIONAL PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR PROFICIENT ENDOMETRIAL CANCER

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Jun 1, 2029

Study completion Jan 30, 2031

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
May 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. Our bodies have a built-in DNA "spell-checker," called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back after previous treatment, it is called advanced or recurrent endometrial cancer. This study is for adults with mismatch repair-pMMR advanced or recurrent endometrial cancer. Participants must meet key criteria, including: * Women who are 18 years or older, and not pregnant at the time of joining the study * pMMR endometrial cancer only * Measurable Stage III disease, Stage IV disease (with or without measurable disease) per FIGO staging, a system doctors use to describe how far cancer has spread in the body, or recurrent (with or without measurable disease) endometrial cancer * Has not received chemotherapy except for chemotherapy given after the main surgery and more than 6 months before relapse * Be in good enough health to receive study treatment. Approximately 600 adult women will be enrolled. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups, with about half in each group. The study is open, meaning both the doctors and participants know what treatment is being given. Participants will receive their assigned treatment through intravenous infusions (medicine is given directly into a vein). The treatment will be given in cycles. Experimental Group will receive new study medicine called PF-08634404 plus chemotherapy. It will be followed by PF 08634404 alone for up to 2 years (35 cycles). Control Group will receive an approved medicine called pembrolizumab plus chemotherapy. It will be followed by pembrolizumab alone for up to 2 years (20 cycles). The study will include regular visits for: * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will come for a final visit within a month to check their health and review any reactions. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records. This helps check health and any new treatments. * Tests will be done every 9 weeks during the first 104 weeks to see how the cancer is responding. After that, tests will be done every 12 weeks.

Conditions

  • Endometrial Neoplasms
  • Endometrial Cancer

Interventions

  • PF-08634404Biological

    Solution for IV infusion

  • PembrolizumabBiological

    Solution for IV infusion

  • Standard of Care ChemotherapyDrug

    Solution for IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) using RECIST v1.1 as assessed by Blinded Independent Central Review (BICR)Time frame: Approximately 36 months

Locations

54 sites in 5 countries. Site status is shown where the registry gives one.

  • Jupiter Medical Center/ Anderson Family Cancer Institute

    Jupiter, Florida · Recruiting

  • Orlando Health Ambulatory Care Center

    Orlando, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Orlando Health Orlando Regional Medical Center

    Orlando, Florida · Recruiting

  • Orlando Health Winnie Palmer Hospital for Women & Babies

    Orlando, Florida · Recruiting

  • Minnesota Oncology Hematology, PA

    Coon Rapids, Minnesota · Recruiting

  • Minnesota Oncology Hematology, PA

    Edina, Minnesota · Recruiting

  • Minnesota Oncology Hematology, PA

    Maple Grove, Minnesota · Recruiting

  • Minnesota Oncology Hematology, PA

    Maplewood, Minnesota · Recruiting

  • Minnesota Oncology Hematology, PA

    Woodbury, Minnesota · Recruiting

  • The Center of Hope

    Reno, Nevada · Recruiting

  • New York Oncology Hematology

    Albany, New York · Not yet recruiting

  • White Plains Hospital

    White Plains, New York · Recruiting

  • Miami Valley Hospital South

    Centerville, Ohio · Recruiting

  • Northwest Cancer Specialists, P.C.

    Happy Valley, Oregon · Recruiting

  • Northwest Cancer Specialists, P.C.

    Portland, Oregon · Recruiting

  • Northwest Cancer Specialists, P.C.

    Tigard, Oregon · Recruiting

  • Sarah Cannon Research Institute- Pharmacy

    Nashville, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - West Texas

    Abilene, Texas · Recruiting

  • Texas Oncology-West Texas

    Amarillo, Texas · Recruiting

  • Texas Oncology - Central South

    Austin, Texas · Recruiting

  • Texas Oncology - Central South

    Austin, Texas · Recruiting

  • Texas Oncology - Central South

    Austin, Texas · Recruiting

  • Texas Oncology-West Texas

    El Paso, Texas · Recruiting

  • Texas Oncology - West Texas

    El Paso, Texas · Recruiting

  • Texas Oncology - West Texas

    El Paso, Texas · Recruiting

  • Texas Oncology - Central South

    Harlingen, Texas · Recruiting

  • US Oncology Investigational Products Center (IPC)

    Irving, Texas · Recruiting

  • Texas Oncology - Central South

    McAllen, Texas · Recruiting

  • Texas Oncology-West Texas

    Midland, Texas · Recruiting

  • Texas Oncology - West Texas

    Odessa, Texas · Recruiting

  • Texas Oncology - Central South

    Waco, Texas · Recruiting

  • Texas Oncology - Central South

    Weslaco, Texas · Recruiting

  • Texas Oncology-West Texas

    Wichita Falls, Texas · Recruiting

  • Virginia Oncology Associates

    Chesapeake, Virginia · Recruiting

  • Virginia Oncology Associates

    Newport News, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Virginia Oncology Associates

    Suffolk, Virginia · Recruiting

  • Virginia Oncology Associates

    Williamsburg, Virginia · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.